| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 91.9 | 85.8 |
| Gross profit | 70.5 | 65.0 |
| Profit before tax | 10.1 | 11.4 |
| Net income | 7.2 | 8.2 |
| EPS (diluted, $ a share) | $0.31 | $0.36 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -12.8% |
|---|---|
| Revenue, year on year | +7.1% |
| Gross margin | 76.7% |
| Operating margin | 10.4% |
10-Q filed with the SEC, NASDAQ: TCMD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Tactile Systems Technology Inc: key numbers
- Share price
- $26.37Close, Nov 16
- Market cap
- $591M
- Shares outstanding
- 22.4MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Tactile Systems Technology Inc
All →Tactile Systems Technology Director William W. Burke Sells $135K of Stock
William W. Burke, Director, sold 5,000 shares of Tactile Systems Technology Inc at $27.00 a share, worth $135K in total on Nov 4, 2026. Shares held after the trade: 50,041 (-9.1%).
- Value
- $135K
- Shares
- 5,000
- Price
- $27.00
- Role
- Director
- Holding change
- -9.1%
- Trade date
- Nov 4, 2026
Tactile Systems Technology Director Laura G. King Sells $120K of Stock
Laura G. King, Director, sold 4,800 shares of Tactile Systems Technology Inc at $25.00 a share, worth $120K in total on Nov 3, 2026. Shares held after the trade: 20,769 (-18.8%).
- Value
- $120K
- Shares
- 4,800
- Price
- $25.00
- Role
- Director
- Holding change
- -18.8%
- Trade date
- Nov 3, 2026
Tactile Systems Technology Financial Results
Tactile Systems Technology reported Q3 2026 total revenue of $91.9 million, a 7% increase year-over-year driven by 13% growth in its core lymphedema product line. While gross margin expanded to 77%, net income decreased to $7.2 million from $8.2 million in the prior year due to increased operating expenses supporting growth initiatives.
- Term
- Q3 2026
“Our results underscore the strength and durability of our core lymphedema business, which delivered its fifth consecutive quarter of double-digit year-over-year revenue growth, while gross margin expanded for the 12th consecutive quarter.”
Sheri Dodd, Chief Executive Officer of Tactile Medical
“We are positioned to capture that opportunity through three connected strategic priorities: expanding access to care, creating value across the patient journey, and broadening treatment options.”
Sheri Dodd, Chief Executive Officer of Tactile Medical